Roxadustat: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), HAS (France) and NICE (England), among others, recommended or restricted roxadustat, while AOTMIT (Poland) and CIPM (Spain) did not recommend it.
The record spans 2 years, opening at AWMSG (Wales) on 24 Jun 2021 and running to 21 Jun 2023.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
4 distinct indication wordings are recorded for roxadustat by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 11 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess roxadustat, on 24 Jun 2021; DMC (Denmark) did not open a file until 21 Jun 2023 — a moderate spread of 2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 7 of 11 dated records fall in 2022 alone.
Restriction is doing real work here: 2 of 7 decisive outcomes narrowed roxadustat to a subgroup rather than accepting or refusing it outright, at NICE (England) and SMC (Scotland).
11 of the 18 agencies in this archive hold a record for roxadustat.
The full ledger for roxadustat reads 3 recommended, 2 not recommended, 2 restricted and 2 advice, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 21 Jun 2023 | Symptomatisk anæmi hos voksne med kronisk nyresygdom | Anbefalet | source |
| AOTMIT (Poland) | 31 Dec 2022 | Evrenzo reimbursement recommendation | not recommended | source |
| CIPM (Spain) | 24 Nov 2022 | Indicación terapéutica autorizada : Evrenzo está indicado para el tratamiento de pacientes adultos con anemia sintomátic… | not financed by the SNS · art. 92 e | source |
| SMC (Scotland) | 8 Aug 2022 | For treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD) | accepted (restricted) | source |
| NICE (England) | 13 Jul 2022 | NICE TA807 | recommended (optimised) | source |
6 further decisions for roxadustat, across 6 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- luspatercept — same ATC class B03X — Antianemics
- epoetin alfa — same ATC class B03X — Antianemics
- darbepoetin alfa — same ATC class B03X — Antianemics
- epoetin zeta — same ATC class B03X — Antianemics
- epoetin theta — same ATC class B03X — Antianemics
- polatuzumab vedotin — also decided by DMC in 2023Q2
Coverage: 11 decisions for roxadustat from 11 agencies, 2021 to 2023. Data to 7 Sep 2026. ATC class B03X — Antianemics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.